- Home
- QLGN vs GLMD Comparison
QLGN vs GLMD Comparison
Compare QLGN & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- GLMD
- Stock Information
- Founded
- QLGN 1996
- GLMD 2000
- Country
- QLGN United States
- GLMD Israel
- Employees
- QLGN N/A
- GLMD N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- GLMD Health Care
- Exchange
- QLGN Nasdaq
- GLMD Nasdaq
- Market Cap
- QLGN 2.8M
- GLMD 3.0M
- IPO Year
- QLGN N/A
- GLMD 2014
- Fundamental
- Price
- QLGN $3.75
- GLMD $1.51
- Analyst Decision
- QLGN
- GLMD Hold
- Analyst Count
- QLGN 0
- GLMD 1
- Target Price
- QLGN N/A
- GLMD N/A
- AVG Volume (30 Days)
- QLGN 10.5K
- GLMD 255.6K
- Earning Date
- QLGN 07-01-2025
- GLMD 06-17-2025
- Dividend Yield
- QLGN N/A
- GLMD N/A
- EPS Growth
- QLGN N/A
- GLMD N/A
- EPS
- QLGN N/A
- GLMD N/A
- Revenue
- QLGN N/A
- GLMD N/A
- Revenue This Year
- QLGN N/A
- GLMD N/A
- Revenue Next Year
- QLGN N/A
- GLMD N/A
- P/E Ratio
- QLGN N/A
- GLMD N/A
- Revenue Growth
- QLGN N/A
- GLMD N/A
- 52 Week Low
- QLGN $2.85
- GLMD $1.15
- 52 Week High
- QLGN $29.44
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- QLGN 51.20
- GLMD 56.28
- Support Level
- QLGN $3.65
- GLMD $1.36
- Resistance Level
- QLGN $3.98
- GLMD $1.60
- Average True Range (ATR)
- QLGN 0.14
- GLMD 0.09
- MACD
- QLGN -0.01
- GLMD 0.03
- Stochastic Oscillator
- QLGN 51.32
- GLMD 79.07
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.